Feb 12, 2021 / 05:00PM GMT
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
Thanks, everybody. Good afternoon. Thanks for joining us for a fireside chat session with Bristol-Myers Squibb. I'm Seamus Fernandez, Guggenheim's global biopharma analyst. We're joined today by Chris Boerner, Chief Commercialization Officer of Bristol-Myers Squibb. And obviously, we have a brief (inaudible) time here. I do apologize we're starting a touch late just because my Internet connection was unstable. So we're using the support of the global network at this point. So...
Christopher S. Boerner - Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
Welcome to the world we live in.
Questions and Answers:
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global PharmaceuticalsExactly. So thanks again, everybody, for joining us. We do have a short time. So Bristol's breadth in oncology is obviously quite